Dark

XBIO
Xenetic Biosciences Inc
stock NASDAQ

At Close

2/3/2023 3:58:30 PM EST

0.7150USD-1.920%(-0.0140)79,038

0.5648Bid 0.8640Ask 0.2992Spread IEX

Pre-market

2/3/2023 9:08:30 AM EST

0.7510USD+3.018%(+0.0220)0

After-hours

1/26/2023 4:02:30 PM EST

0.5700USD0.000%(0.0000)0

Overview Option Chain HistoricalMore

open chart

Market Cap

10.844M

Headquarters

Framingham, Massachusetts, USA

Industry

Biotechnology

Last Split

2019-06-251for12reverse

AAWW BRS ERA XLV

XBIO Stats

Avg. Vol. 10 Day

119,134

Avg. Vol. 30 Day

92,757

Market Cap

10,844,116

Shares Out.

15,166,596

Float

13,057,681

On/Off Exchange

43%/57%

6 Month Beta

0.57

1 Year Beta

0.68

2 Year Beta

0.75

3 Year Beta

0.42

52 Week Low

0.24

52 Week High

1.25

SMA50

0.42

SMA200

0.58

1 Week

+7.47%

1 Month

+93.24%

3 Month

+58.85%

6 Month

-22.74%

1 Year

-29.21%

2 Year

-75.93%

5 Year

-97.16%

Dec 8, 2021

11:24AM EST 'We are expanding the potential of CAR T cell therapy through the development of our XCART technology platform...' -Tweet From Xenetic Biosciences Benzinga

Nov 12, 2021

08:11AM EST Xenetic Biosciences Q3 2021 Net Loss $(1.4)M Benzinga

Oct 15, 2021

04:39PM EDT Xenetic Biosciences Enters Into Amendment Number 1 To MSA With Pharmsynthez To, Among Other Things, Terminate All Work Orders Under MSA Benzinga

Sep 9, 2021

08:08AM EDT Xenetic Biosciences, Inc. Receives Notice Of Allowance For XCART Patent Benzinga

Aug 13, 2021

04:55PM EDT Xenetic Biosciences Files Preliminary Prospectus Related To Resale Of Up To 950K Shares Issued To Selling Stockholder Benzinga

More News

Profile

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART™ has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.

XBIO Stock Summary

Xenetic Biosciences Inc (NASDAQ:XBIO) stock price today is $0.7150, and today's volume is 79,038. XBIO is down -1.920% today. The 30 day average volume is 92,757. XBIO market cap is 10.844M with 15,166,596 shares outstanding.